The U.S. cell and gene therapy clinical trials market, valued at USD 5.36 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2034, driven by accelerating innovation in personalized medicine and robust federal support for advanced therapeutics. While the United States remains the global epicenter for cell and gene therapy (CGT)...